Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C5H11NO2.C2H3Cl3O2 |
| Molecular Weight | 282.549 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(O)C(Cl)(Cl)Cl.C[N+](C)(C)CC([O-])=O
InChI
InChIKey=ONAOIDNSINNZOA-UHFFFAOYSA-N
InChI=1S/C5H11NO2.C2H3Cl3O2/c1-6(2,3)4-5(7)8;3-2(4,5)1(6)7/h4H2,1-3H3;1,6-7H
| Molecular Formula | C2H2Cl3O2 |
| Molecular Weight | 164.395 |
| Charge | -1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | C5H12NO2 |
| Molecular Weight | 118.1543 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CHLORAL BETAINE, a chemical complex of chloral hydrate and betaine, is a nonbarbiturate sedative and hypnotic. It is indicated for sleep induction, preoperative sedation, and daytime sedation. CHLORAL BETAINE is converted to chloral hydrate in the body and its action on the central nervous system is identical with that of chloral hydrate.
CNS Activity
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Beta-Chlor Approved UseCloral Betaine Tablets are used for the short-term treatment of severe insomnia which is interfering with normal daily life and where other therapies have failed. Cloral Betaine Tablets should be used as an adjunct to non-pharmacological therapies. Launch Date1962 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
106 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18243465/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
2,2,2-TRICHLOROETHANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1056 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18243465/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
2,2,2-TRICHLOROETHANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
12.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18243465/ |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
2,2,2-TRICHLOROETHANOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
88 mg/kg single, intravenous Overdose Dose: 88 mg/kg Route: intravenous Route: single Dose: 88 mg/kg Sources: |
healthy, 1.25 |
Disc. AE: Cyanosis, Lethargy... AEs leading to discontinuation/dose reduction: Cyanosis Sources: Lethargy |
20 g single, oral Overdose |
healthy, 27 |
Disc. AE: Hypotension, Ventricular tachycardia... AEs leading to discontinuation/dose reduction: Hypotension Sources: Ventricular tachycardia |
39 mg/kg single, intravenous Overdose Dose: 39 mg/kg Route: intravenous Route: single Dose: 39 mg/kg Sources: |
healthy, 3 |
Disc. AE: Lethargy... AEs leading to discontinuation/dose reduction: Lethargy Sources: |
38 g single, oral Overdose |
unhealthy, 38 |
Disc. AE: Cyanosis, Coma... AEs leading to discontinuation/dose reduction: Cyanosis Sources: Coma Hypotension Ventricular tachycardia |
30 g single, oral Overdose |
healthy, 39 |
Disc. AE: Supraventricular tachycardia, Premature ventricular contractions... AEs leading to discontinuation/dose reduction: Supraventricular tachycardia Sources: Premature ventricular contractions |
20 g single, oral Overdose |
healthy, 42 |
Disc. AE: Chest pain, Tachycardia... AEs leading to discontinuation/dose reduction: Chest pain Sources: Tachycardia |
30 g single, oral Overdose |
healthy, 67 |
Disc. AE: Ventricular tachycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cyanosis | Disc. AE | 88 mg/kg single, intravenous Overdose Dose: 88 mg/kg Route: intravenous Route: single Dose: 88 mg/kg Sources: |
healthy, 1.25 |
| Lethargy | Disc. AE | 88 mg/kg single, intravenous Overdose Dose: 88 mg/kg Route: intravenous Route: single Dose: 88 mg/kg Sources: |
healthy, 1.25 |
| Hypotension | Disc. AE | 20 g single, oral Overdose |
healthy, 27 |
| Ventricular tachycardia | Disc. AE | 20 g single, oral Overdose |
healthy, 27 |
| Lethargy | Disc. AE | 39 mg/kg single, intravenous Overdose Dose: 39 mg/kg Route: intravenous Route: single Dose: 39 mg/kg Sources: |
healthy, 3 |
| Coma | Disc. AE | 38 g single, oral Overdose |
unhealthy, 38 |
| Cyanosis | Disc. AE | 38 g single, oral Overdose |
unhealthy, 38 |
| Hypotension | Disc. AE | 38 g single, oral Overdose |
unhealthy, 38 |
| Ventricular tachycardia | Disc. AE | 38 g single, oral Overdose |
unhealthy, 38 |
| Premature ventricular contractions | Disc. AE | 30 g single, oral Overdose |
healthy, 39 |
| Supraventricular tachycardia | Disc. AE | 30 g single, oral Overdose |
healthy, 39 |
| Chest pain | Disc. AE | 20 g single, oral Overdose |
healthy, 42 |
| Tachycardia | Disc. AE | 20 g single, oral Overdose |
healthy, 42 |
| Ventricular tachycardia | Disc. AE | 30 g single, oral Overdose |
healthy, 67 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://dmd.aspetjournals.org/content/33/10/1429 Page: 1.0 |
major | |||
Sources: https://dmd.aspetjournals.org/content/33/10/1429 Page: 1.0 |
minor |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Oral and rectal absorption of chloral hydrate and its betaine complex. | 1980-02 |
|
| The effects of phenobarbital, chloral betaine, and glutethimide administration on warfarin plasma levels and hypoprothrombinemic responese in man. | 1969-01-01 |
|
| A CHLORAL HYDRATE COMPLEX. CHLORAL BETAINE. (BETA-CHLOR). | 1964-12-28 |
|
| Clinical experience with chloral betaine, a preoperative sedative. | 1963-07 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14212304
To induce sleep, the recommended dosage for adults and children over 12 years of age is 870 mg to 1.7 gm approximately 15 to 30 minutes before bedtime.
For preoperative sedation, the same amounts are given 60 to 90 minutes before surgery.
The suggested sedative dosage is 870 mg given three times daily, with an additional dose at bedtime if necessary.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:33:55 GMT 2025
by
admin
on
Mon Mar 31 18:33:55 GMT 2025
|
| Record UNII |
8680278NRH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
2460
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB06750MIG
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
89808
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | RxNorm | ||
|
1506
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
218-722-1
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
DB01494
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
2218-68-0
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
DTXSID20176716
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
m633
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
C171896
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
100000085429
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
16676
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY | |||
|
8680278NRH
Created by
admin on Mon Mar 31 18:33:55 GMT 2025 , Edited by admin on Mon Mar 31 18:33:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |